PUBLISH YOUR EVENTS!
Boston Professional Events List
Stem Cell Summit (GTC) S
Date
Organizer
Location
Stem Cell Summit
*** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! ***
REGISTER TODAY!
GTCbio is proud to present the Stem Cell Summit 2021, to be held in San Diego, CA. The Stem Cell Summit provides information on cutting-edge developments in all areas of stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development, and the commercialization of stem cells. This summit comprises of presentations, panels and round-table discussions to highlight pre-clinical and clinical studies in regenerative medicine, immunotherapy, stem cell reprogramming, cell therapy in diabetes, regulatory policies regarding stem cell research, manufacturing and other relevant topics.
Stem Cell Summit 2021 includes two back-to-back conferences including joint plenary session:
Conference 1: 15th Stem Cell Research & Regenerative Medicine
-
Advances in Adult & Pluripotent Stem Cell Research
-
Revolution in Immunotherapy
-
What’s in the Pipeline: Pre-clinical & Clinical Strategies
Joint: Plenary Session
-
Where do We Stand with Cell Therapy in Diabetes?
Conference 2: 7th Stem Cell Product Development & Commercialization
-
Regulatory Challenges in Cell Therapy
-
Funding and Partnering
-
Stem Cells for Drug Discovery & Disease Modeling
-
Manufacturing and Scalable Processes
-
Biotech Showcase: Emerging Pipelines
-
Commercialization: Creating Sustainable Business Models
AGENDA
Day 1 - Thursday, April 12, 2021
7:30 Continental Breakfast & Registration
8:15 Opening Remarks by GTCbio
Opening Keynote Session – Historical Perspective and State of the Science & Industry
KEYNOTE
8:30Stem Cells for Diabetics
Douglas Melton Douglas Melton
Professor
Harvard University
Abstract: The advances and remaining challenges...Read More
KEYNOTE
9:15Clinical and Commercial Application of Scaled Human Stem Cell Derivates
Hans Keirstead Hans Keirstead
Chief Executive Officer
AIVITA Biomedical
Abstract: AIVITA Biomedical has developed propr...Read More
10:00 Morning Networking Break
Stem Cell Product Development & Commercialization
Stem Cells for Drug Discovery & Disease Modeling
Moderator: Scott Olson, University of Texas
10:30Stem Cell Derived Human-on-a-chip Systems for Use in Efficacy and Toxicological Investigations in Pre-clinical Drug Discovery
James Hickman James Hickman
Professor, NanoScience Technology Center
University of Central Florida
Abstract: The utilization of human-on-a-chip or...Read More
Stem Cell Research & Regenerative Medicine
Advances in Adult Stem Cell Research
10:30Addressing Age-related Macular Degeneration with Adult Retinal Pigment Epithelial Stem Cells
Sally Temple Sally Temple
Scientific Director
Neural Stem Cell Institute
Abstract: The retinal pigment epithelium (RPE) ...Read More
10:55Ensuring the quality of stem cell derived models for toxicity testing. In: Validation of Alternative Methods for Toxicity Testing.
Glyn Stacey Glyn Stacey
Head of Division
National Institute for Biological Standards and Control
Abstract: The development of in vitro assays fo...Read More
10:55
Douglas Losordo Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
11:20Medical Gas Therapy for SCI: Roles of Adult Neurogenesis
Yang (Ted) D Teng Yang (Ted) D Teng
Director, Laboratory of SCI, Stem Cell & Neurofacilitation Research PM&R and Neurosurgery
Harvard University and Spaulding Rehabilitation Hospital
Abstract: We previously reported that non-toxic...Read More
11:20Bone Marrow Cells for Heart Repair: Cumulative Clinical Evidence and Insights
Buddhadeb Dawn Buddhadeb Dawn
Director, Midwest Stem Cell Therapy Center
University of Kansas Medical Center
Abstract: Numerous clinical trials of bone marr...Read More
11:45
TBA (To Be Announced) TBA (To Be Announced)
11:45
Silviu Itescu Silviu Itescu
Chief Executive Officer & Managing Director
Mesoblast
12:10 Lunch on Your Own
Stem Cell Product Development & Commercialization
Partnering between Industry, Academia, and CROs to Advance Research
1:45Cross-institutional Collaboration in Academia and Industry
Brock Reeve Brock Reeve
Executive Director
Harvard Stem Cell Institute
Stem Cell Research & Regenerative Medicine
Advances in Pluripotent Stem Cell Research
1:45
Mahendra Rao Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
2:10
Anthony Ting Anthony Ting
Vice President
Athersys
2:10
Kristin Baldwin Kristin Baldwin
Professor, Investigator, Dorris Neuroscience Center, Department of Neuroscience California Campus
Scripps Institute
2:35Panel Discussion: Partnering between Industry, Academia, and CROs to Advance Research
Panelist:Alain Vertès Alain Vertès
Managing Director
NxR Biotechnologies GmbH
Panelist:TBA (To Be Announced) TBA (To Be Announced)
Panelist:TBA (To Be Announced) TBA (To Be Announced)
2:35
Kevin Eggan Kevin Eggan
Professor in the Department of Stem Cell and Regenerative Biology
Harvard University
3:00
TBA (To Be Announced) TBA (To Be Announced)
3:25 Afternoon Networking Break
Round Table Sessions
5:15 Networking Reception & Poster Session
Day 1 Day 2
Day - 2 Friday, April 13, 2021
7:15 Breakfast with Mentors from Academia & Industry (RSVP Only)
7:30 Continental Breakfast for All Attendees
Stem Cell Product Development & Commercialization
Manufacturing and Scalable Processes for Cell Therapy
8:30
Katy Spink Katy Spink
Managing Partner
Dark Horse Consulting
Stem Cell Research & Regenerative Medicine
Translation to the Clinic: What’s in the Pipeline
8:30Mesenchymal Stromal Cells – Pre-clinical Science, Clinical Development and Pathway to Marketing Approval
Jacques Galipeau Jacques Galipeau
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison
Abstract: Mesenchymal Stromal Cells have been t...Read More
8:55
Emily Titus Emily Titus
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)
8:55
Deborah Ascheim Deborah Ascheim
Chief Medical Officer
Capricor
9:20Efficient Scale Up/Scale Out of Cell Therapies
Kevin Murray Kevin Murray
Vice President, Global Sales
BioSpherix Medical
Abstract: The first cell therapies have finally...Read More
9:20Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy
Bob Valamehr Bob Valamehr
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.
Abstract: The unique attributes of a combinator...Read More
9:45Cell Therapy Manufacturing, a Continuous Development
Wilfried Dalemans Wilfried Dalemans
Chief Technical Officer
Tigenix
Abstract: Cell therapy manufacturing starts alr...Read More
9:45Clinical Trials in TBI: Preventing the Next Failure
Scott Olson Scott Olson
Assistant Professor, Program in Regenerative Medicine
University of Texas
Abstract: Clinical trials using small molecules...Read More
10:10 Morning Networking Break
Stem Cell Product Development & Commercialization
Funding & Commercialization of Cell Therapy
10:40Accelerating Stem Cell Therapy Development
Gil Sambrano Gil Sambrano
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine
Abstract: The California Institute for Regenera...Read More
Stem Cell Research & Regenerative Medicine
Revolution in Immunotherapy
10:40
Khalid Shah Khalid Shah
Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
11:05
Patrick Keenan Patrick Keenan
Managing Director
Prevail Partners
11:05
Richard Morgan Richard Morgan
Vice President, Immunotherapy
Bluebird Bio
11:30Panel: Funding & Commercialization of Cell Therapy
Panelist:Gail Naughton Gail Naughton
Chief Executive Officer
Histogen
Panelist:Michael May Michael May
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)
Panelist:Gregory Bonfiglio Gregory Bonfiglio
Managing Partner
Proteus Venture Partners
11:30IMPACT: Re-engineered CAR19 T cells have Potent Activity Against Hematologic and Solid Tumors
Paul Rennert Paul Rennert
President & CSO
Aleta Biotherapeutics
Abstract: CAR-CD19 T cell therapeutics are appr...Read More
11:55
MyLinh Duong MyLinh Duong
Senior Scientist
Bellicum Pharmaceuticalsss
Lunch Session: Regulatory Challenges in Cell Therapy
12:30Japanese Policy for Regulatory Science of Stem Cell Therapies
Toshio Miyata Toshio Miyata
Professor, Office for Industry-University Co-Creation
Osaka University
Abstract: Japan government fosters pharmaceutic...Read More
12:55Global Regulatory Policy and Project Update
Melody Eble Melody Eble
Director, Global Regulatory Affairs
Janssen Research & Development, LLC
Abstract: This session will describe select, re...Read More
Award Ceremony & Closing Keynote Lunch Session
KEYNOTE
1:20
Evan Snyder Evan Y. Snyder
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute
KEYNOTE
2:05A Glimpse of the Next 10 Years for Pluripotent Stem Cell-based Therapies
Erin Kimbrel Erin Kimbrel
Senior Director of Development
Astellas Institute for Regenerative Medicine
Keynote Panel Discussion
Moderator: Erin Kimbrel, Astellas Institute for Regenerative Medicine
2:20
Moderator:
Erin Kimbrel Erin Kimbrel
Senior Director of Development
Astellas Institute for Regenerative Medicine
Panelist:
Evan Snyder Evan Y. Snyder
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute
Panelist:
Hans Keirstead Hans Keirstead
Chief Executive Officer
AIVITA Biomedical
3:05 Summit Concludes
SPEAKER
PLENARY KEYNOTE SPEAKERS
Hans Keirstead
Chief Executive Officer
AIVITA Biomedical
Erin Kimbrel
Senior Director of Development
Astellas Institute for Regenerative Medicine
Douglas Melton
Professor
Harvard University
Evan Y. Snyder
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute
PLENARY SPEAKERS
Melody Eble
Director, Global Regulatory Affairs
Janssen Research & Development, LLC
Toshio Miyata
Professor, Office for Industry-University Co-Creation
Osaka University
Stem Cell Product Development & Commercialization
DISTINGUISHED SPEAKERS
Gregory Bonfiglio
Managing Partner
Proteus Venture Partners
Wilfried Dalemans
Chief Technical Officer
Tigenix
Matthew Durdy
Chief Business Officer
Cell Therapy Catapult
James Hickman
Professor, NanoScience Technology Center
University of Central Florida
Patrick Keenan
Managing Director
Prevail Partners
Kevin Murray
Vice President, Global Sales
BioSpherix Medical
Gail Naughton
Chief Executive Officer
Histogen
Brock Reeve
Executive Director
Harvard Stem Cell Institute
Gil Sambrano
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine
Katy Spink
Managing Partner
Dark Horse Consulting
Glyn Stacey
Head of Division
National Institute for Biological Standards and Control
Emily Titus
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)
Alain Vertès
Managing Director
NxR Biotechnologies GmbH
Stem Cell Research & Regenerative Medicine
DISTINGUISHED SPEAKERS
Scott Olson
Assistant Professor, Program in Regenerative Medicine
University of Texas
Deborah Ascheim
Chief Medical Officer
Capricor
Kristin Baldwin
Professor, Investigator, Dorris Neuroscience Center, Department of Neuroscience California Campus
Scripps Institute
Buddhadeb Dawn
Director, Midwest Stem Cell Therapy Center
University of Kansas Medical Center
MyLinh Duong
Senior Scientist
Bellicum Pharmaceuticalsss
Kevin Eggan
Professor in the Department of Stem Cell and Regenerative Biology
Harvard University
Jacques Galipeau
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison
Silviu Itescu
Chief Executive Officer & Managing Director
Mesoblast
Chaim Lebovits
President and CEO
Brainstorm Cell Therapeutics
Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
Marcela Maus
Assistant Professor of Medicine; Director of Cellular Immunotherapy
Harvard Medical School; Cancer Center, Massachusetts General Hospital
Michael May
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)
Richard Morgan
Vice President, Immunotherapy
Bluebird Bio
Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
Paul Rennert
President & CSO
Aleta Biotherapeutics
Khalid Shah
Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
Sally Temple
Scientific Director
Neural Stem Cell Institute
Anthony Ting
Vice President
Athersys
Bob Valamehr
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.
Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for:
- Multiple participant discounts
- Price quotations or visa invitation letters
- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)
- Event sponsorship
NO REFUNDS ALLOWED ON REGISTRATIONS
Prices may go up any time. Service fees included in pricing.
-----------------------------------------------------------------
This event is brought to you by:
Global Technology Community LLC - NewYorkEventsList
http://www.NyEventsList.com
http://www.BostonEventsList.com
http://www.SFBayEventsList.com
-----------------------------------------------------------------
MYL170816CEV MAR170927UPT MYL171025UPD
CHA171109UPT MAR20211124REV VIO180228UPD
MYL180302UPD JOA180315CEV